Tribal Bio is an AI-native platform for biotech. Find and evaluate assets, then build the regulatory submission that gets them filed.
What it does
Search public, licensed and proprietary sources in one place. Every asset comes back scored, with the evidence behind the score.
| Asset | Phase | Modality | Score |
|---|---|---|---|
| TB-2071 | Phase 2 | Small molecule | 94 |
| Ferristat | Phase 1 | Biologic | 88 |
| AV-118 | Preclinical | Small molecule | 81 |
| Nolexid | Phase 2 | Peptide | 76 |
| KR-4402 | Preclinical | ASO | 72 |
Drafts built to eCTD structure, section by section, with sources attached to every claim and gaps flagged before a reviewer finds them.
2.6.6 Toxicology written summary
A 28-day repeat-dose oral toxicity study was conducted in Sprague-Dawley rats at 0, 30, 120 and 300 mg/kg/day.
No treatment-related findings were observed in clinical chemistry or histopathology at or below 120 mg/kg/day.2 sources
Gap: NOAEL not stated for the 28-day study
From lead series to an IND-enabling package: tox strategy, species selection, PK/ADME and study design, with GLP oversight built in. In development.
Tribal assembles submission-ready paperwork from the data you already have, flags what is missing, and writes the sections that do not exist yet.
A 28-day repeat-dose oral toxicity study was conducted in Sprague-Dawley rats at 0, 30, 120 and 300 mg/kg/day.
No treatment-related findings were observed in clinical chemistry or histopathology at or below 120 mg/kg/day.2 sources
Systemic exposure increased approximately dose-proportionally across the range tested.
A review, as it runs
Built for your team
Move a programme from asset selection to a filing without adding headcount.
Deliver more programmes per team, with the same standard of evidence.
Turn source data into submission documents your clients can file.
